Top Research Reports For UnitedHealth, CVS & Morgan Stanley
Zacks Investment Research | Jan 13, 2020 12:40AM ET
Monday, January 13, 2020
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including UnitedHealth Group (UNH), CVS Health (NYSE:CVS) (CVS) and Morgan Stanley (NYSE:MS) (MS). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see
Today's Must Read/h6
Featured Reports/h6
Per the Zacks Analyst, a strong rise in demand for the company's varied defense products leads to organic growth. However, it faces stiff market competition due to peer price pressure.
Enbridge will generate stable fee-based revenues from its $11-billion inventory of midstream growth projects.
The Zacks analyst believes that production ramp-ups at Suncor's major projects, including Fort Hills and Syncrude, should support its growth momentum and earnings.
The Zacks analyst is impressed by the company's top line growth, courtesy of strong ridesharing revenues.
Per the Zacks analyst, Monster Beverage is experiencing continued strength in its energy drinks category driven by its Monster Energy brand.
Per the Zacks analyst, MercadoLibre benefits from solid total payment volume growth which is driven by its strong momentum across online-to-offline payment offerings, thanks to robust MPOS business.
Per the Zacks analyst, Schwab's planned buyouts of TD Ameritrade and USAA's Investment Management Company will help diversify revenues. This along with focus on trading revenues bodes well for growth.
Per the Zacks Analyst, a strong rise in demand for the company's varied defense products leads to organic growth. However, it faces stiff market competition due to peer price pressure.
Enbridge will generate stable fee-based revenues from its $11-billion inventory of midstream growth projects.
The Zacks analyst believes that production ramp-ups at Suncor's major projects, including Fort Hills and Syncrude, should support its growth momentum and earnings.
The Zacks analyst is impressed by the company's top line growth, courtesy of strong ridesharing revenues.
Per the Zacks analyst, Monster Beverage is experiencing continued strength in its energy drinks category driven by its Monster Energy brand.
Per the Zacks analyst, MercadoLibre benefits from solid total payment volume growth which is driven by its strong momentum across online-to-offline payment offerings, thanks to robust MPOS business.
Per the Zacks analyst, Schwab's planned buyouts of TD Ameritrade and USAA's Investment Management Company will help diversify revenues. This along with focus on trading revenues bodes well for growth.
New Upgrades/h6
The Zacks Analyst is impressed with the uptick in Active Riders. This, in turn, is benefiting its top line. Its focus on the market for self-driving cars is also encouraging.
Per the Zacks Analyst, product innovation, solid pipeline of acquisitions as well as focus on cost controls and increasing productivity are likely to drive Manitowoc's results.
The Zacks analyst is bullish about Tandem's strong international rollout of t:slim X2 insulin pump. Huge global demand for diabetes care devices on favourable market trends is another growth driver.n
The Zacks Analyst is impressed with the uptick in Active Riders. This, in turn, is benefiting its top line. Its focus on the market for self-driving cars is also encouraging.
Per the Zacks Analyst, product innovation, solid pipeline of acquisitions as well as focus on cost controls and increasing productivity are likely to drive Manitowoc's results.
The Zacks analyst is bullish about Tandem's strong international rollout of t:slim X2 insulin pump. Huge global demand for diabetes care devices on favourable market trends is another growth driver.n
New Downgrades/h6
The Zacks Analyst is worried about the company's high debt levels. Moreover, the eight-day rail strike at Canadian National crippled its operations, thereby hurting shipment volumes.
The Zacks analyst is concerned about the persistent operating losses incurred by Cardiovascular Systems. Tough competition in the stent and balloon angioplasty market is another concern.
The Zacks analyst believes that prevalent regional uncertainties and fluctuation in automotive production and sales will continue to weigh on Aptiv's business performance.
The Zacks Analyst is worried about the company's high debt levels. Moreover, the eight-day rail strike at Canadian National crippled its operations, thereby hurting shipment volumes.
The Zacks analyst is concerned about the persistent operating losses incurred by Cardiovascular Systems. Tough competition in the stent and balloon angioplasty market is another concern.
The Zacks analyst believes that prevalent regional uncertainties and fluctuation in automotive production and sales will continue to weigh on Aptiv's business performance.
Get The News You Want
undefined Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.